Galecto Announces Pricing of Initial Public Offering

by Ysios Capital

Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company developing therapeutics that are designed to target the biological processes that lie at the heart of fibrosis and impact a broad r...

Read more
Subscribe to Directory
Write an Article

Recent News

Exposure to Heat and Cold During Pregnan...

The research team observed changes in head circumf...

Using mobile RNAs to improve Nitrogen a...

AtCDF3 gene induced greater production of sugars a...

El diagnóstico genético neonatal mejor...

Un estudio con datos de los últimos 35 años, ind...

Highlight

Eosinófilos. ¿Qué significa tener val...

by Labo'Life

​En nuestro post hablamos sobre este interesante tipo de célula del...

A dietary supplement has beneficial effe...

by Institute for Advanced Chemistry of Catalonia (IQAC-CSIC)

Research led by IIBB-CSIC and CIBEREHD scientists identifies S-adenosy...

Photos Stream